![European cancer mortality predictions for the year 2018 with focus on colorectal cancer - Annals of Oncology European cancer mortality predictions for the year 2018 with focus on colorectal cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9ef7b767-d01e-4fdf-bfb8-1b16d695c9cc/gr1_lrg.jpg)
European cancer mortality predictions for the year 2018 with focus on colorectal cancer - Annals of Oncology
![R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis - ScienceDirect R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1097276520309473-fx1.jpg)
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis - ScienceDirect
![Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia - The Journal of Pediatrics Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia - The Journal of Pediatrics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d678766d-4c7b-44d7-b24a-c5b567a2701e/ympd10133-fig-0001.jpg)
Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia - The Journal of Pediatrics
![Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen | eLife Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen | eLife](https://iiif.elifesciences.org/lax/57858%2Felife-57858-fig5-v2.tif/full/,1500/0/default.jpg)
Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen | eLife
![Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/2/e001626/F7.large.jpg)
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer
![Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation | SpringerLink Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-021-04674-x/MediaObjects/277_2021_4674_Fig1_HTML.png)
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation | SpringerLink
![Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen | eLife Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen | eLife](https://iiif.elifesciences.org/lax/57858%2Felife-57858-fig4-v2.tif/full/1500,/0/default.jpg)
Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen | eLife
![Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia | Nature Communications Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-27472-5/MediaObjects/41467_2021_27472_Fig1_HTML.png)
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia | Nature Communications
Washington Capitals on Twitter: "Keep fighting. #CapsFightCancer | @LeidosInc https://t.co/pgoprvjv0b" / Twitter
![Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes - ScienceDirect Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S107476132100087X-fx1.jpg)
Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes - ScienceDirect
![Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia | Journal for ImmunoTherapy of Cancer Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/10/1/e003392/F6.large.jpg)
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia | Journal for ImmunoTherapy of Cancer
![Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/2/e001626/F2.large.jpg?download=true)
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies | Journal for ImmunoTherapy of Cancer
![Efficient Classification of White Blood Cell Leukemia with Improved Swarm Optimization of Deep Features | Scientific Reports Efficient Classification of White Blood Cell Leukemia with Improved Swarm Optimization of Deep Features | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-59215-9/MediaObjects/41598_2020_59215_Fig1_HTML.png)
Efficient Classification of White Blood Cell Leukemia with Improved Swarm Optimization of Deep Features | Scientific Reports
![Digital Applications Targeting Medication Safety in Ambulatory High-Risk CKD Patients | American Society of Nephrology Digital Applications Targeting Medication Safety in Ambulatory High-Risk CKD Patients | American Society of Nephrology](https://cjasn.asnjournals.org/content/clinjasn/16/4/532/F1.large.jpg)